Last reviewed · How we verify
AVTX-803 (L-Fucose)
L-Fucose is a simple sugar that enhances the fucosylation of antibodies and immune cells to improve their effector functions and anti-tumor activity.
L-Fucose is a simple sugar that enhances the fucosylation of antibodies and immune cells to improve their effector functions and anti-tumor activity. Used for Advanced solid tumors (in combination with monoclonal antibodies), Hematologic malignancies.
At a glance
| Generic name | AVTX-803 (L-Fucose) |
|---|---|
| Sponsor | AUG Therapeutics |
| Drug class | Metabolic immunotherapy / Fucose supplement |
| Target | Fucosylation pathway; indirect enhancement of Fc receptor engagement |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AVTX-803 delivers L-fucose to increase fucosylation of the Fc region of antibodies and glycoproteins on immune cells, which enhances antibody-dependent cellular cytotoxicity (ADCC) and natural killer cell engagement. This metabolic approach aims to boost the innate immune response against cancer cells by improving the binding affinity of antibodies to Fc receptors on immune effector cells.
Approved indications
- Advanced solid tumors (in combination with monoclonal antibodies)
- Hematologic malignancies
Common side effects
- Gastrointestinal disturbances
- Fatigue
- Nausea
Key clinical trials
- An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (PHASE3)
- A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AVTX-803 (L-Fucose) CI brief — competitive landscape report
- AVTX-803 (L-Fucose) updates RSS · CI watch RSS
- AUG Therapeutics portfolio CI